Artificial Intelligence (AI) in Biotechnology Market Report Scope & Overview:

The Artificial Intelligence (AI) in Biotechnology Market was valued at USD 3.91 Billion in 2025 and is expected to reach USD 22.50 Billion by 2035, growing at a CAGR of 19.13% from 2026-2035. 

Growth in the Artificial Intelligence (AI) in Biotechnology Market can be attributed to an increased need for rapid drug discovery, low R&D costs, and high success rates during clinical trials. The growing use of AI in fields like genomics, precision medicine, and biomarker discovery is fueling the process of innovation in the field of healthcare. The availability of huge biological data sets, improvement in machine learning algorithms, and the increasing involvement of pharma and biotech companies are adding further impetus to market growth.

In January 2025, the U.S. FDA confirmed rising use of AI in drug development since 2016 and qualified AIM-NASH, the first AI-based tool to support clinical trials by standardizing biopsy scoring, reducing trial timelines, and improving efficiency.

Isomorphic Labs, a Google DeepMind spinout, secured $2.1 billion in Series B funding in 2025 to accelerate expansion of its AI-powered drug discovery platform, strengthening its capabilities in developing next-generation therapeutics and advancing computational drug design.

Market Size and Forecast:

• Market Size in 2025: USD 3.91 Billion

• Market Size by 2035: USD 22.50 Billion

• CAGR: 19.13% from 2026 to 2035

• Base Year: 2025

• Forecast Period: 2026–2035

• Historical Data: 2022–2024

To Get more information on Artificial Intelligence (AI) in Biotechnology Market - Request Free Sample Report

Artificial Intelligence (AI) in Biotechnology Market Trends:

• Rising demand for faster drug discovery and development is driving the Artificial Intelligence (AI) in biotechnology market.

• Growing adoption in genomics, proteomics, and bioinformatics is boosting market growth.

• Expansion of precision medicine and personalized healthcare is fueling AI integration in biotech workflows.

• Increasing focus on reducing R&D costs and accelerating clinical trials is shaping adoption trends.

• Advancements in machine learning, deep learning, and predictive modeling are enhancing biological data analysis.

• Rising investments in biotech startups and AI-driven research platforms are supporting market expansion.

• Collaborations between pharmaceutical companies, biotech firms, and AI technology providers are accelerating innovation and global adoption.

U.S. Artificial Intelligence (AI) in Biotechnology Market was valued at USD 1.34 Billion in 2025 and is expected to reach USD 6.98 Billion by 2035, growing at a CAGR of 17.90% from 2026-2035. 

The U.S. Artificial Intelligence (AI) in Biotechnology Market is experiencing growth owing to heavy investments in research and development in the field of pharmaceuticals, wide application of AI-based drug discovery technologies, and developed healthcare infrastructure. The rising application of genomics, precision medicine, and clinical data analytics is fueling growth.

Artificial Intelligence (AI) in Biotechnology Market Segment Highlights:

• By Component, Software segment dominated the Artificial Intelligence (AI) in Biotechnology Market in 2025 with 48% market share; Services segment fastest growing (CAGR).

• By Application, Drug Discovery & Development segment dominated the Artificial Intelligence (AI) in Biotechnology Market in 2025 with 44% market share; Clinical Trials & Optimization segment fastest growing (CAGR).

• By End User, Pharmaceutical Companies segment dominated the Artificial Intelligence (AI) in Biotechnology Market in 2025 with 46% market share; CRO & CDMO segment fastest growing (CAGR).

Artificial Intelligence (AI) in Biotechnology Market Segment Analysis:

By Component, Software segment dominates the Artificial Intelligence (AI) in Biotechnology Market, Services segment expected to grow fastest

The Software Segment led the Artificial Intelligence (AI) in Biotechnology Market in 2025 due to the increased usage of AI-based platforms for data analysis, molecular modeling, predictive analytics, and drug discovery. The biotech and pharma companies are using advanced software segments for processing of large sets of biological data in order to make their research more efficient. The improvements in machine learning models, deep learning frameworks, and bioinformatics software segments further supported the leadership of the software segment.

The services segment is expected to grow at the highest rate over the forecast period as a result of high demand for services such as AI integration, training models, data management, and consulting. Most companies do not have adequate AI knowledge and, thus, seek services from specialized vendors for the deployment and optimization of AI solutions targeting biotechnology. The rising complexity of biological data and need for customized AI solutions in drug discovery and clinical trials is further boosting the services segment’s growth.

By Application, Drug Discovery & Development segment dominates the AI in Biotechnology Market, Clinical Trials & Optimization segment expected to grow fastest

The Drug Discovery & Development application accounted for the largest share of the Artificial Intelligence (AI) in Biotechnology Market in 2025. AI technologies help in speeding up the process of target identification, molecule screening, and lead optimization. They also cut down the time and cost spent on R&D work. The increasing number of investments made by the pharmaceutical industry and the increasing application of techniques related to computational biology further helped the application hold the largest market share.

The Clinical Trials & Optimization segment is projected to experience the highest CAGR over the forecast period, driven by increased need for effective trial designs and monitoring. The use of AI systems is becoming common in optimizing the accuracy of trials, failure rate minimization, and resource allocation. The increase in complexity in clinical trials and the need for data-driven decision-making in regulations is boosting the uptake of AI in clinical trials.

By End User, Pharmaceutical Companies segment dominates the AI in Biotechnology Market, CRO & CDMO segment expected to grow fastest

Pharmaceutical Companies segment dominated the Artificial Intelligence (AI) in Biotechnology Market in 2025 owing to their high investing capability and utilization of AI in discovering drugs, optimizing pipelines, and developing personalized medicines. They are increasingly incorporating AI in their operations for improving their R&D efficiency, decreasing development expenses, and accelerating product development cycles. The intensifying competition among pharmaceutical firms has further driven the implementation of AI technology.

The CRO & CDMO segment is anticipated to experience the fastest growth rate during the forecast period due to an increase in the outsourcing of research, development, and manufacturing services by pharma and biotech firms. The rapid adoption of AI technologies by these firms for increasing efficiency, streamlining clinical trial management, and optimizing the drug discovery process is expected to propel the market's growth in the coming years.

Market Regional Analysis:

North America Artificial Intelligence (AI) in Biotechnology Market Insights

North America held the largest market share in the artificial intelligence (AI) in biotechnology market, accounting for around 42%, due to the presence of top biotechnology companies, highly developed healthcare sector, and significant investments in AI-based drug discovery processes. North America has several advantages, including active research & development operations, quick implementation of precision medicines, and favorable regulatory environment that facilitates innovation. Moreover, increasing cooperation between technology companies and pharmaceutical corporations, along with increased access to big data on biological information, is fueling the growth of AI.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Artificial Intelligence (AI) in Biotechnology Market Insights

The Asia Pacific AI in biotechnology market is expected to have the highest CAGR because of the fast-paced digital transformation in the healthcare industry and increasing investment in biotechnological research. The growing use of artificial intelligence in drug development, expanding pharmaceutical production capacity, and strong governmental backing for life science innovations are some factors fueling market growth. Furthermore, a huge number of patients, better healthcare facilities, and partnerships between biotech companies and technology providers are contributing to the increasing use of advanced artificial intelligence solutions.

Europe Artificial Intelligence (AI) in Biotechnology Market Insights

The Europe artificial intelligence (AI) in biotechnology market is growing owing to robust pharmaceutical research framework, rising investments towards precision medicines, and rising deployment of AI-based drug discovery systems. Collaboration among biotechnology firms, academia, and healthcare institutions has been contributing significantly to advancements in genomics and clinical studies. Favorable policies from governments for digital health transition and stringent efforts towards drug development that are compliant with regulations have also been favoring AI adoption. Furthermore, rising demand for personalized medicines and clinical trials optimization software solutions has been driving the market's growth trajectory.

Middle East & Africa and Latin America Artificial Intelligence (AI) in Biotechnology Market Insights

The artificial intelligence (AI) biotechnology market in the Middle East & Africa and Latin America regions is witnessing gradual changes because of growing digitalization in healthcare and increasing funding in biotechnology research. The expansion in pharmaceutical industry operations, the advancement of healthcare facilities, and the increasing awareness of AI in medical applications are driving the adoption process. The governments of these countries have shifted their focus towards the improvement of healthcare facilities and international collaborations in the development of drugs. Nevertheless, poor R&D and budgetary issues are acting as barriers to adoption.

Market Growth Drivers: Accelerating Drug Discovery Timelines and Reducing R&D Costs Driving Rapid Adoption of AI Technologies in Biotechnology Sector:

As a consequence of the rising expectation among the pharma and biotech companies to streamline drug discovery processes, AI technology is becoming increasingly prevalent within the area of biotechnology. AI is helping in the rapid identification of drug compounds, their predicted behavior, and biological modeling, thus reducing the requirement for extensive experimentation within laboratories. This is helping in reducing costs associated with research and development and improving clinical trials pipelines. This rise in AI adoption is being driven by the increasing rivalry within the pharma industry, along with the desire to bring out more drugs rapidly into the market.

Market Restraints: Data Privacy Concerns and Strict Regulatory Frameworks Limiting Large-Scale Deployment of AI-Based Biotechnology Solutions:

Stringent regulations of patient data protection and biotechnological research severely constrains the scalability of AI applications in biotechnology. Adherence to privacy laws demands that the patient data should be handled in a safe manner, making the operations of companies more complex. Other challenges faced include misuse of data, ethical concerns about decision-making by AI algorithms, and opacity of the algorithms' functioning. Also, there are long approval procedures that slow down the release of new AI-powered medical and diagnostic technologies into the market. This makes the implementation of AI systems more difficult even though they are highly promising.

Market Opportunities: Rising Investments in Precision Medicine and Personalized Healthcare Creating Strong Growth Opportunities for AI in Biotechnology:

The increasing trend towards precision medicine and personalized care has opened up many prospects for the incorporation of artificial intelligence into biotechnology. Through artificial intelligence techniques, genetic profiling, patient history, and disease patterns can be analyzed to come up with customized treatments. Advances in genomics studies and biomarkers have been instrumental in driving innovations in personalized medicine. Artificial intelligence is being used by pharmaceutical firms to refine patient stratification, optimize clinical trials, and enhance treatment outcomes. There is a growing need for personalized medicine approaches that will drive more AI adoption in biotechnology.

Recent Developments:

• 2026: Illumina launched Billion Cell Atlas mapping 1 billion CRISPR-modified cells to train AI models for drug discovery. It supports collaborations with AstraZeneca, Merck, and Eli Lilly for disease mechanism research and target validation.

• 2026: Eli Lilly expanded AI-native drug discovery strategy with NVIDIA partnership, combining wet-lab experimentation and generative AI models to accelerate molecule design and clinical pipeline productivity.

• 2025: NVIDIA and Eli Lilly launched a $1B AI co-innovation lab focused on drug discovery using BioNeMo and physical AI systems. The collaboration integrates lab robotics and AI models to accelerate molecule discovery and clinical development.

• 2024: NVIDIA launched CUDA-X microservices for biology, chemistry, and genomics enabling AI-powered drug discovery workflows. These tools help companies build generative biology applications and accelerate imaging and molecular simulation across healthcare pipelines.

• 2024: Recursion completed integration with Exscientia, combining AI models and clinical pipelines. The merged platform strengthens end-to-end drug discovery using machine learning, automation, and large-scale biological datasets for faster therapeutic development.

Artificial Intelligence (AI) in Biotechnology Market Key Players:

• NVIDIA Corporation

• Illumina Inc.

• IBM Corporation

• Recursion Pharmaceuticals

• Insilico Medicine

• AstraZeneca plc

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Novartis AG

• Sanofi S.A.

• Amgen Inc.

• Johnson & Johnson (Janssen)

• Bristol-Myers Squibb Company

• Merck & Co., Inc.

• Gilead Sciences Inc.

• Biogen Inc.

• Abbott Laboratories

• Tempus AI

• Schrödinger Inc.

• Exscientia plc

Artificial Intelligence (AI) in Biotechnology Market Report Scope: